SCHEDULE 13G

Amendment No. 0
Insmed Incorporated
Common Stock
Cusip #457669208


Cusip #457669208
Item 1:	Reporting Person - FMR LLC
Item 4:	Delaware
Item 5:	1,599,487
Item 6:	0
Item 7:	1,599,487
Item 8:	0
Item 9:	1,599,487
Item 11:	6.935%
Item 12:	    HC


Cusip #457669208
Item 1:	Reporting Person - Edward C. Johnson 3d
Item 4:	United States of America
Item 5:	0
Item 6:	0
Item 7:	1,599,487
Item 8:	0
Item 9:	1,599,487
Item 11:	6.935%
Item 12:	IN




	SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(c)



Item 1(a).	Name of Issuer:

		Insmed Incorporated

Item 1(b).	Name of Issuer's Principal Executive Offices:

		8720 Stony Point Parkway
		Suite 200
		Richmond, VA  23235
		USA

Item 2(a).	Name of Person Filing:

		FMR LLC

Item 2(b).	Address or Principal Business Office or, if None,
Residence:

		82 Devonshire Street, Boston,
Massachusetts  02109

Item 2(c).	Citizenship:

		Not applicable

Item 2(d).	Title of Class of Securities:

		Common Stock

Item 2(e).	CUSIP Number:

		457669208

Item 3.	This statement is filed pursuant to Rule 13d-1(c)

Item 4.	Ownership

	(a)	Amount Beneficially Owned:	1,599,487

	(b)	Percent of Class:	6.935%

	(c)	Number of shares as to which such
person has:

	(i)	sole power to vote or to direct
the vote:	1,599,487

	(ii)	shared power to vote or to
direct the vote:	0

	(iii)	sole power to dispose or to
direct the disposition of:	1,599,487

	(iv)	shared power to dispose or to
direct the disposition of:	0



Item 5.	Ownership of Five Percent or Less of a Class.

	Not applicable.

Item 6.	Ownership of More than Five Percent on Behalf of Another
Person.

	Various persons have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the
sale of, the Common Stock of Insmed Incorporated.  The
interest of one person, Beacon Bioventures Limited
Partnership, a Delaware limited partnership, in the Common
Stock of Insmed Incorporated, amounted to 1,588,720 shares
or 6.889% of the total outstanding Common Stock at March
01, 2011 (adjusted to reflect the 1-for-10 reverse stock split
effective as of the close of business on March 2, 2011).

Item 7.	Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.

	See attached Exhibit A.

Item 8.	Identification and Classification of Members of
the Group.

	Not applicable.  See attached Exhibit A.

Item 9.	Notice of Dissolution of Group.

	Not applicable.

Item 10.	Certification.

	By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in any
transaction having such purpose or effect.

Signature

	After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.

March 09, 2011
Date

 /s/ Scott C. Goebel
Signature

Scott C. Goebel
Duly authorized under Power of Attorney
effective as of June 1, 2008 by and on behalf of FMR LLC
and its direct and indirect  subsidiaries


	SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(c)



	Beacon Bioventures Limited Partnership and Beacon
Bioventures Principals Limited Partnership, 82 Devonshire
Street, Boston, MA 02109, each a Delaware limited
partnership, are the beneficial owners of 1,588,720 shares and
10,767 shares, respectively, or 6.889% and 0.047%
respectively, of the Common Stock outstanding.  Beacon
Bioventures Advisors Limited Partnership is the general
partner of Beacon Bioventures Limited Partnership and
Beacon Bioventures Principals Limited Partnership.  The
general partner of Beacon Bioventures Advisors Limited
Partnership is Fidelity Biosciences Corp., a wholly-owned
subsidiary of FMR LLC.

	Members of the family of Edward C. Johnson 3d,
Chairman of FMR LLC, are the predominant owners, directly
or through trusts, of Series B voting common shares of FMR
LLC, representing 49% of the voting power of FMR LLC.
The Johnson family group and all other Series B shareholders
have entered into a shareholders' voting agreement under
which all Series B voting common shares will be voted in
accordance with the majority vote of Series B voting common
shares.  Accordingly, through their ownership of voting
common shares and the execution of the shareholders' voting
agreement, members of the Johnson family may be deemed,
under the Investment Company Act of 1940, to form a
controlling group with respect to FMR LLC.



	SCHEDULE 13G - TO BE INCLUDED IN
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(c)
	RULE 13d-1(f)(1)  AGREEMENT

	The undersigned persons, on March 09, 2011, agree
and consent to the joint filing on their behalf of this Schedule
13G in connection with their beneficial ownership of the
Common Stock of Insmed Incorporated at March 01, 2011
(adjusted to reflect the 1- for-10 reverse stock split effective as
of the close of business on March 2, 2011).

	FMR LLC

	By /s/ Scott C. Goebel
	Scott C. Goebel
	Duly authorized under Power of Attorney effective as
of June 1, 2008, by and on behalf of FMR LLC and its direct
and indirect subsidiaries

	Edward C. Johnson 3d

	By /s/ Scott C. Goebel
	Scott C. Goebel
	Duly authorized under Power of Attorney effective as
of June 1, 2008, by and on behalf of Edward C. Johnson 3d